Hagens Berman Sobol Shapiro Investigations

Genzyme Corporation

Date Started: July 31, 2009

Hagens Berman Sobool Shapiro is investigating Genzyme Corporation (NASDAQ:GENZ), a Cambridge, Massachusetts-based biotechnology company, on behalf of investors.

Genzyme's share price has fallen more than 35 percent from 83.25 per share to below $53 per share, costing investors more than $8 billion, published reports state. The law firm is investigating whether the company withheld material information that may have caused stocks to plummet.

The investigation comes following reports that Genzyme may have delayed news concerning manufacturing problems.

If you are a Genzyme shareholder and would like to speak with attorneys about your rights, please fill out our contact form, e-mail genzyme@hbsslaw.com or call (510) 725-3033.